# US HIV Drugs Market

> US HIV Drugs Market Research Report: Size, Share, Trend Analysis By Types (nucleoside, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, fusion inhibitors, ccr5 antagonist) and By End Users (hospitals & clinics, specialty centers) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 3.7%
- **2024:** $ 5.5 Billion
- **2025:** $ 5.7 Billion
- **2035:** $ 8.2 Billion
- **Key Players:** Gilead Sciences (US), ViiV Healthcare (GB), Bristol-Myers Squibb (US), Merck & Co. (US), Johnson & Johnson (US), AbbVie (US), AstraZeneca (GB), Teva Pharmaceutical Industries (IL), Mylan (US)

**Report ID:** MRFR/Pharma/17844-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-hiv-drugs-market-19391

---

## Market Summary

## **US HIV Drugs Market Overview**

As per MRFR analysis, the US HIV Drugs Market Size was estimated at 6.13 (USD Billion) in 2023. The US HIV Drugs Market Industry is expected to grow from 6.5(USD Billion) in 2024 to 10 (USD Billion) by 2035. The US HIV Drugs Market CAGR (growth rate) is expected to be around 3.994% during the forecast period (2025 - 2035).

### **Key US HIV Drugs Market Trends Highlighted**

The US HIV Drugs Market has been influenced by several key market drivers that focus on improving treatment options and patient care. There has been a notable shift towards the development of long-acting injectable formulations and single-tablet regimens, enhancing adherence and convenience for patients. The increasing prevalence of HIV and the need for ongoing management have propelled investments in research and development, leading to innovative therapies. Additionally, the US government supports initiatives aimed at ending the HIV epidemic by 2030, which drives both funding and attention to HIV treatment and prevention strategies.

Opportunities for growth in the US HIV Drugs Market are significant, particularly in expanding access to care for underserved populations.With initiatives to increase testing and awareness, there is an untapped market for effective treatment options that cater specifically to diverse demographics. Furthermore, telehealth services are being increasingly utilized, providing patients with access to consultations and ongoing support, especially during the COVID-19 pandemic, which has accelerated digital health solutions. 

This evolving landscape presents a chance to enhance patient engagement and streamline treatment adherence. Recently, trends in the US HIV Drugs Market also indicate an increasing focus on preventative measures, such as pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), which are gaining traction among at-risk populations.Efforts to destigmatize HIV and promote education on treatment options have resulted in a shift in how the condition is perceived. Collaborations among pharmaceutical companies, non-profits, and healthcare providers are being seen more frequently to improve treatment outcomes and expand access to medications, ultimately reflecting the growing commitment to combat HIV in the US.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US HIV Drugs Market Drivers**

### **Rising Incidence of HIV Infections**

The increase in the number of Human Immunodeficiency Virus (HIV) infections in the United States significantly drives the US HIV Drugs Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 34,800 people received an HIV diagnosis in the year 2020, indicating a 20% increase in new infections compared to the previous years.

As the number of individuals diagnosed with HIV rises, the need for effective antiretroviral therapy (ART) becomes more crucial, thereby promoting the demand for HIV drugs.Moreover, the CDC's efforts in raising awareness about HIV and its treatment options have intensified, leading to higher testing rates and subsequently more patients in need of medication. This trend is expected to persist, fueling the US HIV Drugs Market Industry growth as the healthcare system adapts to manage a larger patient population effectively.

### **Advancements in Drug Development**

The US HIV Drugs Market Industry is bolstered by significant advancements in drug development, particularly in the area of Research and Development (R&D). For instance, agencies such as the National Institutes of Health (NIH) have invested over $3 billion annually in HIV/AIDS research, leading to innovative treatment options and improved patient outcomes.

The introduction of long-acting injectables and combination therapies have been pivotal in enhancing adherence to treatment plans and reducing viral loads among patients.Such advancements not only offer better management of HIV but also contribute to the overall market growth as pharmaceutical companies launch new products based on the evolving research landscape.

### **Government Support and Funding**

Government support and funding play a vital role in shaping the US HIV Drugs Market Industry. Through initiatives like the Ryan White HIV/AIDS Program, federal funding has increased access to necessary HIV medications and services for low-income individuals. In 2021, the program allocated about $2.3 billion specifically to address the HIV epidemic, assisting approximately 500,000 individuals in accessing critical healthcare services.

This financial backing from the government not only aids patients in acquiring essential medications but also encourages pharmaceutical companies to invest in the US HIV Drugs Market Industry by developing new drugs and therapies aimed at combating this ongoing health crisis.

## **US HIV Drugs Market Segment Insights**

### **HIV Drugs Market Type Insights**

The US HIV Drugs Market is significantly shaped by the various Types of medications utilized in the treatment and management of HIV. This segment encompasses several categories, including nucleoside, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, fusion inhibitors, and CCR5 antagonists, each playing a pivotal role in the therapeutic landscape. Nucleoside reverse transcriptase inhibitors (NRTIs) have been a cornerstone therapy since the early days of HIV treatment, contributing to viral suppression and improved patient outcomes. 

They effectively hinder the virus's ability to replicate, making them vital in first-line treatment regimens. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have emerged as a dynamic alternative with unique mechanisms of action, providing options for patients who may have resistance to NRTIs. These two classes form a robust foundation for antiretroviral therapy, underscoring their significance in ongoing HIV management strategies.Moreover, protease inhibitors (PIs) have remained influential, recognized for their potency and ability to overcome viral resistance. They inhibit the protease enzyme necessary for viral maturation, showcasing the breadth of treatment methodologies available in the US HIV Drugs Market. 

Integrase inhibitors, which block the integrase enzyme involved in viral DNA sequencingintegration into the host genome, illustrate a more recent advancement in HIV therapy. Their streamlined dosing regimens appeal to patients due to improved convenience and adherence. Meanwhile, fusion inhibitors represent a niche but crucial category, preventing the HIV virus from entering host cells, thus addressing the infection from a different angle.

Lastly, CCR5 antagonists have gained prominence as they specifically target a cellular receptor necessary for the virus to enter immune cells, highlighting innovations in HIV treatment options.Collectively, these Types within the US HIV Drugs Market signal significant advancements in treatment regimens and are underpinned by ongoing Research and Development efforts. 

With the focus on evolving treatment paradigms, the segment not only reflects the current landscape but also indicates potential future directions as new therapies emerge to enhance patient care. The interplay between these classes illustrates the commitment to providing effective anti-HIV therapies, which is essential given the ongoing need for accessible and effective treatment options for individuals living with HIV in the United States. The robustness of the US HIV Drugs Market, supported by its diverse treatment types, underlines the critical role of ongoing innovation and research in combating this global health challenge.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **HIV Drugs Market End User Insights**

The US HIV Drugs Market is significantly influenced by the End User segmentation, predominantly comprising hospitals and clinics, as well as specialty centers. Hospitals and clinics serve as primary access points for HIV treatment, playing a crucial role in patient management and care. These facilities are often associated with comprehensive healthcare systems that enable timely diagnosis, treatment, and follow-up services.

Specialty centers are essential for providing targeted care and support for individuals living with HIV, offering specialized services like counseling, medication management, and access to clinical trials.As of recent reports, a substantial portion of HIV patients rely on these centers, which is a testament to their importance in managing the disease effectively. 

The growth and advancements in treatment options, coupled with increased awareness and education surrounding HIV, further boost the demand within these segments. Additionally, the evolving landscape of healthcare policies in the US promotes integration and collaboration within these facilities, amplifying their capabilities to cater to the growing patient population. Overall, the End User segmentation, especially hospitals and specialty centers, plays a pivotal role in shaping the dynamics of the US HIV Drugs Market, driving innovation, and enhancing patient outcomes.

## **US HIV Drugs Market Key Players and Competitive Insights**

The US HIV Drugs Market has witnessed significant advancements and intense competition among pharmaceutical companies striving to cater to the growing demand for effective treatments. This sector has evolved with a focus on innovative therapies, including antiretroviral treatments and preventative measures, in a bid to manage and ultimately eradicate HIV infections. Competitors are continuously engaged in research and development to enhance drug efficacy, improve patient adherence, and establish competitive pricing strategies.

The landscape is shaped by a blend of established players and emerging companies, all striving to secure a foothold in a market characterized by its urgency and the critical need for therapies that manage the disease effectively while addressing associated healthcare challenges.

Merck and Co has established a prominent position within the US HIV Drugs Market, primarily through its strong portfolio of pharmaceutical products and a robust pipeline that enhances its market presence. The company has leveraged its extensive experience in drug development and commercialization, empowering it to remain competitive. The strength of Merck lies in its commitment to research and innovation, producing therapies that focus on viral suppression and improved patient outcomes. Furthermore, Merck benefits from a well-distributed network that enables efficient delivery of its products to healthcare providers, ensuring patients have access to the latest treatment options.

The company's collaboration with healthcare professionals and organizations also fosters trust and long-term partnerships, which are essential in the dynamic landscape of HIV treatment.

Bristol Myers Squibb has made significant contributions to the US HIV Drugs Market with its distinctive offerings and strategic initiatives that emphasize patient care and innovation. The company is known for key products that address various aspects of HIV treatment, focusing on efficacy, safety, and patient adherence. Its strong market presence is bolstered by its commitment to research and development, expanding its product line to meet the evolving needs of healthcare providers and patients alike. Additionally, Bristol Myers Squibb has engaged in strategic mergers and acquisitions that strengthen its portfolio and facilitate access to cutting-edge therapies.

The company's dedication to addressing health disparities and improving access to HIV treatment programs further underscores its commitment to patient-centric approaches within the US market. Through these efforts, Bristol Myers Squibb continues to solidify its position as a key player in the ongoing battle against HIV.

### **Key Companies in the US HIV Drugs Market Include**

### **US HIV Drugs Market Industry Developments**

Recent developments in the US HIV Drugs Market reflect significant advancements and collaborations among key players. In September 2023, Gilead Sciences launched a new long-acting injectable therapy to enhance patient adherence to HIV treatment. Zymeworks continues progressing in its HIV drug candidates, with encouraging results from ongoing clinical trials. In terms of mergers and acquisitions, both Merck and Co and Bristol Myers Squibb announced exploratory discussions for strategic partnerships to bolster their portfolios in the HIV sector in August 2023, aiming to enhance market reach and drug development capabilities.

Johnson and Johnson also reported advancements in their HIV Research and Development initiatives, focusing on innovative therapies. 

The market has seen a notable shift toward personalized medicine, with companies like ViiV Healthcare leading efforts to tailor treatments to individual patient needs, promoting better outcomes. Over the past two years, the valuation of HIV drug companies has steadily increased due to rising demand for effective treatments and the ongoing commitment to eliminate HIV diseases, with a reported growth of over 10% in market size in 2022. These trends underscore the dynamic environment in the US HIV drugs market, with a focus on innovation and strategic collaboration.

## **US HIV Drugs Market Segmentation Insights**

### **HIV Drugs Market Type Outlook**

### **HIV Drugs Market End User Outlook**

## Market Drivers

### Rising Prevalence of HIV

The increasing prevalence of HIV in the US is a critical driver for the HIV Drugs Market. According to the Centers for Disease Control and Prevention (CDC), approximately 1.2 million people in the US are living with HIV, with around 38,000 new infections reported annually. This persistent prevalence necessitates ongoing demand for effective antiretroviral therapies and other treatment options. The growing number of individuals requiring treatment fuels the market, as healthcare providers seek to offer the latest advancements in HIV medications. Furthermore, the rising awareness and testing initiatives contribute to early diagnosis, which is essential for effective management of the disease. As more individuals are diagnosed and enter treatment, the hiv drugs market is likely to experience sustained growth, driven by the need for innovative and effective therapeutic solutions.

### Advancements in Drug Development

Innovations in drug development are significantly impacting the hiv drugs market. The introduction of novel antiretroviral therapies, including long-acting injectables and combination therapies, has transformed treatment paradigms. Recent advancements have led to the development of drugs that not only improve adherence but also enhance the quality of life for patients. For instance, the FDA has approved several new medications that target HIV with greater efficacy and fewer side effects. The market is projected to grow as pharmaceutical companies invest heavily in research and development, aiming to bring forth next-generation therapies. This focus on innovation is expected to drive competition among manufacturers, ultimately benefiting patients with more effective treatment options. The ongoing evolution in drug development is a key factor that shapes the dynamics of the hiv drugs market.

### Increased Focus on Mental Health

The recognition of mental health as a crucial component of overall health is influencing the hiv drugs market. Individuals living with HIV often face mental health challenges, including depression and anxiety, which can impact treatment adherence and health outcomes. As healthcare providers become more aware of the interplay between mental health and HIV, there is a growing emphasis on integrated care models that address both physical and mental health needs. This holistic approach encourages the development of treatment plans that incorporate mental health support alongside antiretroviral therapy. Consequently, pharmaceutical companies are exploring options that not only target the virus but also consider the psychological well-being of patients. The increased focus on mental health is likely to shape the future landscape of the hiv drugs market, promoting comprehensive care strategies.

### Government Initiatives and Funding

Government initiatives and funding play a pivotal role in shaping the hiv drugs market. The US government has committed substantial resources to combat HIV through programs such as the Ryan White HIV/AIDS Program, which provides comprehensive care and treatment for individuals living with HIV. In recent years, federal funding for HIV prevention and treatment has increased, reflecting a commitment to reducing new infections and improving health outcomes. This financial support enables healthcare providers to access the latest medications and treatment options, thereby enhancing patient care. Additionally, public health campaigns aimed at increasing awareness and reducing stigma surrounding HIV contribute to higher testing rates and treatment uptake. As government efforts continue to evolve, they are likely to have a lasting impact on the hiv drugs market, fostering an environment conducive to growth and innovation.

### Growing Demand for Personalized Medicine

The trend towards personalized medicine is emerging as a significant driver in the hiv drugs market. Tailoring treatment regimens to individual patient profiles, including genetic factors and drug resistance patterns, enhances the effectiveness of HIV therapies. As healthcare providers increasingly adopt precision medicine approaches, the demand for specialized testing and targeted therapies is likely to rise. This shift not only improves treatment outcomes but also aligns with the broader trend of individualized healthcare. Pharmaceutical companies are responding by developing drugs that cater to specific patient needs, thereby expanding their market reach. The integration of personalized medicine into HIV treatment protocols may lead to more efficient use of resources and improved patient adherence, ultimately contributing to the growth of the hiv drugs market.

## Future Outlook

The [HIV Drugs Market](https://www.marketresearchfuture.com/reports/hiv-drugs-market-8456) is projected to grow at a 3.7% CAGR from 2025 to 2035, driven by advancements in treatment options, increasing awareness, and supportive government policies.

**New opportunities:**

- Expansion of telehealth services for HIV management Development of long-acting injectable formulations Partnerships with community organizations for outreach programs

By 2035, the market is expected to achieve substantial growth, reflecting ongoing innovation and increased access.

## Segment Insights

### By Type: Nucleoside (Largest) vs. Integrase Inhibitors (Fastest-Growing)

The US HIV Drugs Market shows a diverse distribution of market share among various drug types, with Nucleoside Reverse Transcriptase Inhibitors commanding the largest share due to their long-established efficacy and widespread use. Non-Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors also hold significant positions, while Integrase Inhibitors are emerging strongly, reflecting a shift towards newer therapeutic options. Fusion Inhibitors and CCR5 Antagonists represent smaller shares but play crucial roles in specific treatment regimens.

Growth trends in the US hiv drugs market are driven by advancements in drug formulation and an increasing number of patients accessing treatment. Integrase Inhibitors are leading the charge as the fastest-growing segment, reflecting a trend towards more tolerable and effective therapies. The expansion of healthcare access and the ongoing research into HIV treatment modalities are also important factors that contribute to the dynamic nature of this market segment.

Nucleoside (Dominant) vs. Integrase Inhibitors (Emerging)

Nucleoside Reverse Transcriptase Inhibitors remain the dominant class in the US hiv drugs market, appreciated for their foundational role in HIV therapy and proven effectiveness over many years. These drugs are widely prescribed, making them crucial for most treatment regimens. In contrast, Integrase Inhibitors are recognized as an emerging class that shows significant growth potential. Their mechanism of action offers unique advantages in terms of patient adherence and achieving viral suppression. As healthcare providers increasingly turn to newer therapies, Integrase Inhibitors are positioned for rapid adoption, particularly in treatment-naive patients and those seeking alternatives to older therapies.

### By End User: Hospitals & Clinics (Largest) vs. Specialty Centers (Fastest-Growing)

The US HIV Drugs Market is significantly influenced by the presence of Hospitals & Clinics, which dominate the segment with a substantial market share. These establishments play a crucial role in administering antiretroviral therapy to a large patient population, thus driving demand for hiv drugs. Specialty Centers are emerging as a vital component of the market as well, providing targeted care for specific populations, further enriching the landscape of hiv treatment options available to patients.

In recent years, growth trends have shown a notable shift towards Specialty Centers, which are rapidly gaining traction due to their focus on personalized patient care and innovative treatment approaches. Factors such as the increasing prevalence of HIV and the growing emphasis on integrated care models are propelling these centers to the forefront. As awareness around HIV continues to rise, both Hospitals & Clinics and Specialty Centers will play essential roles in shaping the future of treatment and care in this segment.

Healthcare Facilities: Hospitals & Clinics (Dominant) vs. Specialty Centers (Emerging)

Hospitals & Clinics represent the backbone of the hiv drugs market, characterized by their extensive resources and multidisciplinary care teams that offer a broad range of services. These facilities are equipped to handle critical care scenarios and are typically the first point of contact for patients seeking hiv treatment. On the other hand, Specialty Centers are carving out their niche by focusing on specific therapeutic areas, offering tailored services that cater to the unique needs of a diverse patient population. While Hospitals & Clinics dominate in volume, Specialty Centers are increasingly recognized for their expertise and innovation, making them important stakeholders in the care continuum.

## Competitive Benchmarking

The HIV drugs market is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Gilead Sciences (US), ViiV Healthcare (GB), and Merck & Co. (US) are at the forefront, each employing distinct strategies to enhance their market presence. Gilead Sciences (US) continues to lead with its robust portfolio of antiretroviral therapies, emphasizing research and development to introduce next-generation treatments. ViiV Healthcare (GB), a joint venture focused solely on HIV, leverages its specialized expertise to drive innovation, while Merck & Co. (US) is expanding its offerings through strategic collaborations aimed at enhancing treatment accessibility and efficacy.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with a mix of established players and emerging biotech firms. This fragmentation allows for diverse treatment options, yet the collective influence of major companies shapes pricing strategies and market access, creating a competitive environment that is both challenging and opportunistic.
In October Gilead Sciences (US) announced a partnership with a leading telehealth provider to enhance patient access to HIV treatment through digital platforms. This strategic move underscores Gilead's commitment to integrating technology into healthcare delivery, potentially improving adherence rates and patient outcomes. By leveraging telehealth, Gilead aims to reach underserved populations, thereby expanding its market share and reinforcing its leadership position.
In September ViiV Healthcare (GB) launched a new long-acting injectable treatment, which has shown promising results in clinical trials. This innovation not only addresses the need for more convenient treatment options but also positions ViiV as a pioneer in the evolving landscape of HIV care. The introduction of this product is likely to enhance patient adherence and satisfaction, further solidifying ViiV's reputation as a leader in HIV therapeutics.
In August Merck & Co. (US) entered into a collaboration with a non-profit organization to improve access to HIV medications in low-income communities. This initiative reflects Merck's strategic focus on corporate social responsibility and its recognition of the importance of equitable healthcare access. By aligning its business objectives with social impact, Merck is likely to enhance its brand reputation while contributing to broader public health goals.
As of November current trends in the HIV drugs market indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in drug development and patient management. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine market dynamics, emphasizing the importance of delivering value through cutting-edge solutions and improved patient experiences.

## Recent News & Developments

Recent developments in the US HIV Drugs Market reflect significant advancements and collaborations among key players. In September 2023, Gilead Sciences launched a new long-acting injectable therapy to enhance patient adherence to HIV treatment. Zymeworks continues progressing in its HIV drug candidates, with encouraging results from ongoing clinical trials. In terms of mergers and acquisitions, both Merck and Co and Bristol Myers Squibb announced exploratory discussions for strategic partnerships to bolster their portfolios in the HIV sector in August 2023, aiming to enhance market reach and drug development capabilities.

Johnson and Johnson also reported advancements in their HIV Research and Development initiatives, focusing on innovative therapies. 

The market has seen a notable shift toward personalized medicine, with companies like ViiV Healthcare leading efforts to tailor treatments to individual patient needs, promoting better outcomes. Over the past two years, the valuation of HIV drug companies has steadily increased due to rising demand for effective treatments and the ongoing commitment to eliminate HIV diseases, with a reported growth of over 10% in market size in 2022. These trends underscore the dynamic environment in the US HIV drugs market, with a focus on innovation and strategic collaboration.

## Report Scope

| MARKET SIZE 2024 | 5.5(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 5.7(USD Billion) |
| MARKET SIZE 2035 | 8.2(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.7% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Gilead Sciences (US), ViiV Healthcare (GB), Bristol-Myers Squibb (US), Merck & Co. (US), Johnson & Johnson (US), AbbVie (US), AstraZeneca (GB), Teva Pharmaceutical Industries (IL), Mylan (US) |
| Segments Covered | Type, End User |
| Key Market Opportunities | Advancements in personalized medicine and targeted therapies enhance treatment options in the hiv drugs market. |
| Key Market Dynamics | Regulatory changes and technological advancements drive innovation and competition in the HIV drugs market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US HIV drugs market in 2024?**
A: The overall market valuation of the US HIV drugs market was $5.5 Billion in 2024.

**Q: What is the projected market valuation for the US HIV drugs market by 2035?**
A: The projected market valuation for the US HIV drugs market is $8.2 Billion by 2035.

**Q: What is the expected CAGR for the US HIV drugs market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US HIV drugs market during the forecast period 2025 - 2035 is 3.7%.

**Q: Which companies are considered key players in the US HIV drugs market?**
A: Key players in the US HIV drugs market include Gilead Sciences, ViiV Healthcare, Bristol-Myers Squibb, Merck & Co., Johnson & Johnson, AbbVie, AstraZeneca, Teva Pharmaceutical Industries, and Mylan.

**Q: What segment had the highest valuation in the US HIV drugs market in 2024?**
A: In 2024, the segment with the highest valuation in the US HIV drugs market was Hospitals & Clinics, valued at $3.3 Billion.

**Q: What is the projected valuation for the Nucleoside segment by 2035?**
A: The projected valuation for the Nucleoside segment in the US HIV drugs market is $2.2 Billion by 2035.

**Q: How does the valuation of Integrase Inhibitors change from 2024 to 2035?**
A: The valuation of Integrase Inhibitors in the US HIV drugs market increases from $1.3 Billion in 2024 to $1.9 Billion by 2035.

**Q: What is the expected growth for the Specialty Centers segment from 2024 to 2035?**
A: The Specialty Centers segment is expected to grow from $2.2 Billion in 2024 to $3.4 Billion by 2035.

**Q: What was the valuation of Protease Inhibitors in 2024?**
A: The valuation of Protease Inhibitors in the US HIV drugs market was $1.2 Billion in 2024.

**Q: What is the projected valuation for CCR5 Antagonists by 2035?**
A: The projected valuation for CCR5 Antagonists in the US HIV drugs market is $0.6 Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-hiv-drugs-market-19391*